Drugs / TAA-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03843294 | Jun 2019 → May 2023 overdue | Hodgkins lymphoma, diffuse large B-cell lymphoma | Catherine Bollard | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAA-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03843294 ↗ |
| Target | PRAME | “TAA-specific T cells (TAA-Ts) targeting WT1, PRAME, and Survivin were safe and associated with prolonged time to progression in solid tumors.” PMID 34495306 ↗ Jan 2022 |
| Target | WT1 | “TAA-specific T cells (TAA-Ts) targeting WT1, PRAME, and Survivin were safe and associated with prolonged time to progression in solid tumors.” PMID 34495306 ↗ Jan 2022 |